BioMarin Pharmaceutical (BMRN) Investor Day 2024 summary

Strategic vision and transformation

• Unveiled a new strategy focused on innovation, growth, and value commitment, aiming to accelerate value creation for all stakeholders and transform the operating model with three dedicated business units for accountability and efficiency.

• Leadership team strengthened with new appointments and a clear succession plan, supporting execution of the new strategy.

• Prioritized pipeline and made decisive organizational changes, including a $500 million cost transformation program to optimize structure and profitability.

• Business development is positioned as an optional growth lever, not required for the core plan, with a focus on deals under $1.5 billion and a disciplined approach to external innovation.

Financial guidance and capital allocation

• Targeting $4 billion in revenue by 2027 and mid-teen CAGR through 2034, placing the company in the top quartile of biopharma peers.

• Aiming for 40% non-GAAP operating margin by 2026, sustained at 40%+ beyond, driven by cost efficiencies and operating leverage.

• Projecting over $1.25 billion in annual operating cash flow by 2027, enabling significant capital deployment flexibility.

• Capital allocation priorities are organic growth, selective external innovation, and eventual return of capital to shareholders, supported by a new $600 million revolving credit facility.

Growth drivers and commercial strategy

• Skeletal conditions business, led by Voxzogo, is the primary growth engine, with five new indications in development and a total addressable patient population of 420,000 across served geographies.

• Voxzogo has achieved strong initial penetration in achondroplasia, with over 80% of the market still untapped and expansion planned into at least 20 more countries by 2027.

• Enzyme therapies portfolio has delivered 8% CAGR over the past three years and is expected to sustain or accelerate growth through targeted diagnosis, adherence initiatives, and emerging market expansion.

• Commercial strategy includes tailored go-to-market approaches for each indication, leveraging established global infrastructure and patient support programs.